Neurocritical Care News

NEW ORLEANS – Autopsy results in otherwise healthy people who died from COVID-19 suggest that immunoglobulin therapy may be an effective treatment choice, Avindra Nath, MD, said at the American Psychiatric Association annual meeting.

Patients treated for stroke at non-urban hospitals in New Zealand experience poorer outcomes and face reduced access to crucial stroke interventions across the entire care spectrum, according to a study published in Neurology.

The FDA has extended its new drug application review of AMX0035, a combination of sodium phenylbutyrate and taurursodiol for the treatment of ALS, Amylyx Pharmaceuticals Inc. announced in a press release.

The COVID-19 pandemic was a likely cause for worsened disparities in buprenorphine and naltrexone access for opioid use disorder among minority groups compared with white patients, per a study published in JAMA Network Open.

VeriSIM Life announced it will partner with neuroscience firm Total Brain to develop new drugs for the treatment of a wide range of neurological disorders, the company announced through a press release.

NIH researchers using machine learning models identified key characteristics of people who have or likely have long COVID.

Genentech announced that the FDA approved a label extension for Evrysdi to include infants younger than 2 months with spinal muscular atrophy.

Seizure- and epilepsy-related emergency department visits decreased during the COVID-19 pandemic compared with pre-pandemic levels, with the largest drop seen among young children, per a study in MMWR.

The FDA has granted priority review to Reata Pharmaceuticals Inc.’s new drug application for omaveloxolone to treat patients with Friedreich’s ataxia.

Age variability in symptom onset of Alzheimer’s disease in those with Down syndrome was comparable to those who experienced autosomal dominant AD, while mortality was also similar, according to a study published in JAMA Network Open.